Callan Family Office LLC Invests $435,000 in DexCom, Inc. $DXCM

Callan Family Office LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 6,452 shares of the medical device company’s stock, valued at approximately $435,000.

Other institutional investors also recently bought and sold shares of the company. Reflection Asset Management purchased a new stake in DexCom in the fourth quarter worth about $25,000. Ascentis Independent Advisors bought a new position in shares of DexCom in the first quarter worth about $25,000. MCF Advisors LLC purchased a new position in shares of DexCom during the 4th quarter valued at about $32,000. Wellington Grp LLC lifted its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares in the last quarter. Finally, DV Equities LLC bought a new position in shares of DexCom during the 4th quarter valued at approximately $36,000. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of several analyst reports. TD Cowen reissued a “buy” rating on shares of DexCom in a report on Friday, July 31st. Barclays reiterated an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective for the company. Bank of America decreased their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Citigroup restated a “buy” rating and set a $88.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $88.71.

DexCom Trading Down 0.2%

Shares of DXCM opened at $88.96 on Thursday. The firm has a market cap of $33.57 billion, a P/E ratio of 35.16, a price-to-earnings-growth ratio of 1.50 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The company has a 50 day simple moving average of $78.50 and a two-hundred day simple moving average of $71.33.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. On average, equities analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider owned 328,970 shares in the company, valued at $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the transaction, the executive vice president owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. The trade was a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.